Compare ZIM & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZIM | NAMS |
|---|---|---|
| Founded | 1945 | 2019 |
| Country | Israel | Netherlands |
| Employees | N/A | 100 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.5B |
| IPO Year | 2020 | N/A |
| Metric | ZIM | NAMS |
|---|---|---|
| Price | $26.40 | $34.79 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $18.18 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 1.6M | 783.3K |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.50% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.96 |
| Revenue Next Year | N/A | $540.65 |
| P/E Ratio | $3.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.33 | $15.72 |
| 52 Week High | $29.97 | $42.00 |
| Indicator | ZIM | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 49.39 | 58.39 |
| Support Level | $25.77 | $34.05 |
| Resistance Level | $29.13 | $37.43 |
| Average True Range (ATR) | 0.48 | 1.75 |
| MACD | -0.03 | 0.53 |
| Stochastic Oscillator | 55.41 | 74.00 |
ZIM Integrated Shipping Services Ltd is an asset-light container liner shipping company. It offers tailored services, including land transportation and logistical services, specialized shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. Its services include Cargo Services, Digital Services, Schedules, and Shipping Trades and Lines. Geographically, it derives a majority of its revenue from the Pacific trade region.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.